Posted on 27/04/2010 in Pharmaceutical Company Product News Novo Nordisk has highlighted findings from a recent clinical trial which underlines the advantages of its diabetes treatment Victoza.
According to results published in the Lancet, type 2 diabetes patients trialled using Novo Nordisk's human GLP-1 analogue showed a better response than a comparison group using the DPP-4 inhibitor treatment Januvia.
Victoza patients experienced greater reductions in HbA1c, fasting plasma glucose and body weight, while they were also more likely to report overall satisfaction with their treatment regime.
Dr Richard Pratley of the diabetes and metabolism translational medicine unit at the University of Vermont College of Medicine said: "With so many patients still struggling to lower their blood sugar, Victoza represents an effective new option."
The drug has been approved in European nations since July 3rd 2009.
Earlier this month, Novo Nordisk announced the commencement of a new global survey of haemophilia patients, which is designed to collect data on the condition's wider psychological and social impact.Other news stories from 27/04/2010
Read more in the Zenopa News Archive
How this news is generated
|
